Article | May 13, 2020

Integrating Complex And Disparate Laboratory Data In Your Clinical Trial

Source: LabConnect

By Dale Mitchell and Jim Carter, LabConnect

Integration Flow

As the focus for new drug development has transitioned from large blockbuster drugs to niche drugs for smaller patient populations, the biopharmaceutical landscape has changed dramatically. Companies now face the dual challenge of developing complex drugs for more targeted groups of patients combined with increasingly competitive timelines. Biomarkers serve as a valuable tool in achieving these goals, as they help researchers identify those patients who will most likely respond to a medication. Biomarkers also improve response rates, determine appropriate dosing, and minimize complications. Therefore, by adopting a method for seamlessly integrating and validating increasingly complex biomarker data, you can streamline your clinical trials, allowing life-saving drugs to reach the market – and patients – faster.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: